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Introduction
Chronic daily headache (CDH), defined as 15 or more
headache days per month [1], may severely affect the quali-
ty of life of the patients, impairing their work and non-work
activities and reducing their productivity [2]. Among these
patients, those who are refractory to treatment are left with
a debilitating headache disorder and constitute the most
challenging population in a headache clinic.
Antiepileptic drugs play an important role in the treat-
ment of headache disorders [3] and other pain syndromes
[4–6]. Topiramate, a new generation broad-spectrum anti-
convulsant, has recently been tried as a preventive drug in
the treatment of various headache syndromes. These stud-
ies show that topiramate may have a place in the preven-
tion of migraine [7–10], transformed migraine [7] and
cluster headache [7, 11].
We hereby report on our experience with topiramate,
shown to have possible significant adverse events (e.g.,
somnolence, paraesthesias and cognitive deficits), in the
treatment of patients with CDH who were refractory to
multiple previous treatments.
Methods
We included patients with CDH who were refractory to treat-
ment trials with multiple modalities such as valproic acid, tri-
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Abstract Chronic daily headache
(CDH) is a debilitating disorder
that becomes a treatment challenge
in patients refractory to the treat-
ment. We hereby report our experi-
ence with topiramate treatment in
patients with refractory CDH. The
study design was a prospective,
protocol-based follow-up and retro-
spective analysis of headache
diaries. We treated with topiramate
at slowly increased moderate incre-
ments 11 CDH patients who were
refractory to multiple previous
treatments. Topiramate treatment
was effective in 7 patients (64%).
The treatment resulted in a 66%
(median) decrease of the headache
days per week and a significant
decrease in headache severity, a
reduction of the headache hours per
day, and weekly analgesic con-
sumption. These effects continued
for an average follow-up of 8±4
months. The average effective dose
was 100 mg/day. Slowly increasing
the drug at moderate increments
resulted in high tolerability of topi-
ramate. We found topiramate to be
an effective long-standing treatment
option for patients with refractory
CDH. Slow increments of the
dosage contributed to high tolera-
bility of the drug.
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cyclic antidepressants, serotonin specific reuptake inhibitors,
non-steroidal anti-inflammatory drugs, analgesics, greater occip-
ital nerve blocks and acupuncture, homeopathic or herbal treat-
ments (used by some of the patients). We included males or
females older than 18 years in whom the CDH was not due to
medication overuse. The patients had an ophthalmological
examination prior to the treatment and their weight was moni-
tored. Data was collected through daily headache diaries. To
improve tolerability, we started topiramate at a daily dose of
12.5 mg and increased the dosage biweekly by 12.5 mg, given
bid. Weekly increments were further used if no adverse events
were noted.
The Institutional Review Board approved the study accord-
ing to the Helsinki rules and informed consent was obtained
from each subject.
Results
Eleven patients with refractory CDH were treated with
topiramate. The average age of the patients was 51±13
years (64% women). The median duration of the CDH at
the time of the study entry was 5 years (range 2–25 years).
Five patients had CDH of transformed migraine type. The
rest had CDH of tension-type headache; among them one
patient had recurrent surgeries for CSF shunting (initially
performed for the treatment of hydrocephalus) and 2
patients had headache related to a post-traumatic stress
disorder (Table 1).
Topiramate successfully relieved headaches in 7
patients (64%). The number of headache days per week
decreased by 66% (median; range 0%–96%); the
headache hours per day were reduced by 50% (median;
range 0–90%) and the severity of the headache lessened
by 50% (median; range 0%–79%). In the 7 responders to
topiramate the weekly analgesic consumption decreased
by 74%±22% (average, range 50%–100%) (Table 2).
These effects continued for an average follow-up of 8±4
months (range 5–14 months).
Initial headache relief was noted after 5±4 weeks of
treatment. The maximal daily dose of topiramate used by
the patients who had headache relief was 100 mg (medi-
an; range 25–250 mg) (Table 2). The 4 patients with no
headache relief discontinued the treatment due to adverse
effects (patients 10, 11; Table 2) or due to lack of efficacy
(2 patients). The analgesic consumption of these patients
did not change during the study follow-up.
Mild and tolerable adverse events of topiramate were
reported by 7 patients (64%) and consisted of tiredness (2
patients), acral paraesthesias (2 patients) and difficulty in
concentrating (2 patients) (Table 2). Weight loss and weight
gain (3 kg) were noted in 2 patients.
Discussion
In this study we found that topiramate was an effective
treatment for patients with refractory CDH. Of theses
patients, considered as ‘treatment unresponsive’, 7
patients (64%) gained with topiramate a significant reduc-
tion in the headache frequency, severity and analgesic
consumption.
Patients with CDH do respond somewhat to various
medical treatments and therefore the available population
was limited, but represented the most challenging popula-
tion in a headache clinic. Although this was an open
Table 1 Demographic data and CDH characteristics
Patient no. Gender Age, years CDH type CDH duration, years
1 F 55 Tr. Mig. 2
2 F 63 Tr. Mig. 6
3 F 57 Tr. Mig. 2
4 M 23 TTH* 4
5 F 54 Tr. Mig. 5
6 F 69 TTH 15
7 M 49 TTH* 10
8 F 46 TTH 5
9 F 49 Tr. Mig. 4
10 M 58 TTH 25
11 M 34 TTH** 10
Tr. Mig., transformed migraine; TTH, tension-type headache
*Patient diagnosed with post-traumatic stress disorder
**Patient had shunt insertion for the treatment of hydrocephalus
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uncontrolled study of a small population, the effect of the
treatment that continued for 8±4 months is much longer
than that expected for placebo. We therefore assume that
it represents, in these particular our patients, a true effect
of the treatment. Our results are in accordance with early
observations on the usefulness of topiramate in trans-
formed migraine [7] and we show here that the drug may
be effectively used for other types of CDH.
We increased the dose of topiramate gradually in
small increments. Although there were some adverse
events, we assume that this modality of drug augmenta-
tion enabled the high tolerability of topiramate during the
long follow-up.
Conclusions
We found topiramate to be an effective, long-lasting pre-
ventive treatment option for patients with refractory CDH.
Small increments of the dosage over many weeks con-
tributed to high tolerability of the drug.
Table 2 Results of topiramate treatment in patients with refractory CDH
Patient no. CDH Time to Follow-up, Maximal Decrease in Decrease in Decrease  in Decrease in Adverse 
type effect, months dose, headache headache headache analgesics effects
weeks given bid, days, % hours/day, % severity, % consumption,
mg/day %
1 Tr. Mig. 5 13.5 100 79 50 79 50
2 Tr. Mig. 1 5.5 25 96 0 0 96 Unpleasant
feeling
3 Tr. Mig. 8 9 75 66 90 50 90
4 TTH* 3 12 75 75 0 75 75
5 Tr. Mig. 4 5 125 17 54 0 50
6 TTH 4 5 150 0 50 0 55 Diff. word 
finding,
tiredness
7 TTH* 13 6 250 0 0 60 100 Acral paraest.
8 TTH None 2.5 137.5 Acral paraest.,
diff. concentrating
9 Tr. Mig. None 5 200 Irritability, diffic.
concentrating,
tiredness
10 TTH None 1 100 Headache
increase
11 TTH** None 1 50 Dizziness,
instability
Tr. Mig., transformed migraine; TTH, tension-type headache
*Patient diagnosed with post-traumatic stress disorder
**Patient had shunt insertion
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